AETHLON MEDICAL INC (AEMD Q2 FY2025 earnings call

• Jim Frakes was appointed permanent CEO in October; key objectives when appointed were moving forward in oncology and reducing expenses. Expense reductions optimized resource allocation for oncology work. • Steve LaRosa discussed Australian oncology study: first two patients enrolled at Royal Adelaide Hospital, second patient enrolled, Pindara Private Hospital open for enrollment; third site in Sydney in process with contingent ethics approval. • India trial: Medanta Medicity Hospital has ethics approval, enrollment pending CDSCO device import approval. • Hemopurifier has potential applications in oncology (binding exosomes to improve anti-PD-1 therapy response) and life-threatening viral infections (shown effectiveness in binding various viruses).

Aethlon Medical does not have distinct product segments with revenue contributions detailed. As of September 30, 2024, cash balance was approximately $6.9 million. Consolidated operating expenses for the fiscal quarter ended September 30, 2024, were approximately $2.9 million, a decrease from $3.2 million in the same period of 2023. Net loss decreased to approximately $2.8 million in the fiscal quarter ended September 30, 2024, from approximately $3 million in the same quarter of 2023.

• Next earnings call for fiscal third quarter ending December 31, 2024, will coincide with filing of quarterly report on Form 10-Q in February 2025.

• Forward-looking statements are subject to significant risks and uncertainties, detailed in the company's annual report on Form 10-K for the fiscal year ended March 31, 2024, most recent quarterly report on Form 10-Q, and other SEC filings.

Q: Marla Marin asked about whether the first 2 patients enrolled in the Australia study are representative of different solid tumor types.

A: Steven LaRosa and James Frakes stated the first 2 patients had 2 different tumor types representative of those treated with anti-PD-1.

Q: Marla Marin asked if the company is highly confident of ethics committee approval at the third Australian location.

A: Steven LaRosa said the third site has contingent ethics board approval, just needing radiation assessment update, and they have confidence it will be approved.

Q: Jeremy Pearlman asked about why there are two separate trials in India and Australia with the same endpoint.

A: Steven LaRosa said differences in patient populations (genetics, comorbid illnesses) between Australia and India warrant separate data sets.

Q: Jeremy Pearlman asked about enrollment timeline and data from the Australia trial.

A: Steven LaRosa explained the trial is a sequential escalating cohort study, with first data on safety expected in January, and EV and T-cell data to follow into summer next year once cohorts are completed.